Monthly Archives: May 2019

16 May 2019

PolyProx – Parkwalk UCEF VI investment

By |May 16th, 2019|

Parkwalk are delighted to welcome PolyProx to its portfolio following an investment from the University of Cambridge Enterprise Fund VI.

PolyProx Therapeutics is a biotechnology company focused on the discovery and development of a new class of drugs, Polyproxin™ molecules, to treat cancer and neurodegenerative diseases. Polyproxin™ molecules are biopharmaceuticals that selectively target disease-causing proteins […]

Parkwalk – why record CGT receipts mean EIS has a key role to play

By |May 13th, 2019|

The original article appeared in Professional Adviser
As HMRC announces a record £9.2bn in CGT receipts, Parkwalk looks at flows into the tax-efficient sector in 2018/19 and why EIS should play an increasingly important part in client conversations

And breathe … though not for long.

The tax-year end is always a busy time for tax-efficient fund managers […]

Parkwalk – Opportunities EIS Fund was the largest EIS fund in 2018/19

By |May 1st, 2019|

We are delighted to report that the Parkwalk Opportunities EIS fund was the largest EIS fund in 2018/19, raising over £60 million.

Importantly, we continue to average 12 months for a subscription to be fully invested. So the next few weeks is a good time to subscribe to the Parkwalk Opportunities EIS fund as your clients […]